ARGX
argenx SE
argenx SE (ARGX) Q2 2026 earnings
Published Jul 23, 2026
AI summary
- Revenue $1.52B, up 60% from $949M a year ago.
- GAAP EPS $7.32, up from $3.74 a year ago.
- Argenx reported second quarter product net sales of $1.5 billion, a 60% increase compared to the prior year.
- The company achieved a quarterly profit of $472 million, up from $245 million in the same period last year.
- Growth was driven by the VYVGART franchise, which recently expanded its label to include all gMG serotypes.
Results vs analyst consensus
Revenue
Reported
$1.52B
Consensus not captured before release
+60% YoY
EPS · GAAP
Reported · GAAP diluted EPS
$7.32
Consensus not captured before release
Prior year: $3.74
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- Operating expenses increased to $1.0 billion, driven by higher research and development and commercialization costs.
- The company recorded a $8 million foreign exchange loss for the quarter compared to a gain in the prior year.
Read original report
Source: argenx SE press release · SEC Form 6-K exhibit 99.1